Do you plan to initiate combination therapy with an SGLT-2 inhibitor and finerenone, instead of an SGLT-2 inhibitor alone, when treating patients with proteinuric chronic kidney disease and type 2 diabetes in light of the CONFIDENCE trial findings?  

I would start one (typically the SGLT-2 inhibitor) then add finerenone potentailly later. If both are started simultaneously and there is an AE then both may have to be stopped. I prefer to see that one is tolerated, then start another

No. I would go step by step and evaluate the response. First blood pressure control, then ACE/ARB, then SGLT-2 and finally finerenone. At each step would evaluate the effect on proteinuria and if achieve significant reduction and goal level would consider whether next step is necessary.